|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
|||||||||||||||||
|
|||||||||||||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=s8D7049B0-3D3E-11EF-BFD8-0EB784CE164B&I=39IZM&T=&OP=Display&O=html&O1=13010806&O2=954925534050&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DPatient%2520reported%2520outcomes%2520and%2520tolerability%2520in%2520patients%2520receiving%2520ripretinib%2520versus%2520sunitinib%2520after%2520imatinib%2520treatment%2520in%2520INTRIGUE%253A%2520A%2520phase%25203%2520open-label%2520study%26rft.au%3DBlay%252C%2520Jean-Yves%26rft.au%3DGelderblom%252C%2520Hans%26rft.au%3DGeorge%252C%2520Suzanne%26rft.au%3DJones%252C%2520Robin%2520Lewis%26rft.date%3D2022-06-01%26rft.eissn%3D1527-7755%26rft.epage%3D11541%26rft.externalDBID%3Dn%252Fa%26rft.externalDocID%3D10_1200_JCO_2022_40_16_suppl_11541%26rft.genre%3Darticle%26rft.issn%3D0732-183X%26rft.issue%3D16_suppl%26rft.jtitle%3DJournal%2520of%2520clinical%2520oncology%26rft.spage%3D11541%26rft.volume%3D40%26rft_id%3Dinfo%253Adoi%252F10.1200%252FJCO.2022.40.16_suppl.11541%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-UNPAYWALL-getFullTxt-object,2-EZB-FREE-00999_FREELY_AVAILABLE_EZB_JOURNALS-getFullTxt-object,3-GFMER_FREE_MEDICAL_JOURNALS-getFullTxt-object,4-COBIB_SI_LCL-getHolding-object,5-DOI-getDOI-object,6-ELSEVIER_SCOPUS_FIS_LCL-getAbstract-object,7-NCBI_PUBMED_FREE-getAbstract-object,8-ISI_WEB_OF_SCIENCE-getAuthor-object,9-ISI_JOURNAL_CITATION_REPORTS_SCIENCE_EDITION-getCitedJournal-object,10-REFWORKS_EXPORT_TOOL-getReference-object,11-SHERPA_RoMEO_LCL-getWebService-object,12-GOOGLE_SCHOLAR_FREE-getWebSearch-object,13-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=1.29538&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:13010806-s8D7049B0-3D3E-11EF-BFD8-0EB784CE164B" timestamp="2024-07-08T17:27:15Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:954925534050</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.</jnl:atitle>
<jnl:jtitle>Journal of Clinical Oncology</jnl:jtitle>
<jnl:date>2022-06-01</jnl:date>
<jnl:spage>11541</jnl:spage>
<jnl:epage>11541</jnl:epage>
<jnl:coden>JCONDN</jnl:coden>
<jnl:issn>0732-183X</jnl:issn>
<jnl:volume>40</jnl:volume>
<jnl:issue>16_suppl</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>1527-7755</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:coden>JCONDN</jnl:coden>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:88f5cccac7979ca6a43982db952737bb803b199c</ctx:identifier>
<ctx:identifier>urn:UUID:s8D7049B0-3D3E-11EF-BFD8-0EB784CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)